Abstracts tagged "meta-analysis and rheumatoid arthritis (RA)"

Abstract Number: 1524 • 2018 ACR/ARHP Annual Meeting
Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Jean Tayar², Natalia Zamora³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Two JAK inhibitors are currently approved by different agencies worldwide for their use in patients with rheumatoid arthritis. The safety profile of these agents…
Abstract Number: 2483 • 2018 ACR/ARHP Annual Meeting
Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials
Andreas Kerschbaumer¹, Bruno Bierbaumer², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Independent, Munich, Germany, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is among the most intensively studied chronic inflammatory musculoskeletal diseases. Over the past two decades numerous new compounds have been tested…
Abstract Number: 438 • 2017 ACR/ARHP Annual Meeting
High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts
Jeffrey R. Curtis¹, Cecilie Heegaard Brahe², Mikkel Østergaard³, Merete Lund Hetland², Karen Hambardzumyan⁴, Saedis Saevarsdottir⁴, Xingbin Wang⁵, Eric H. Sasso⁵ and Tom W.J. Huizinga⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) test uses a validated algorithm with 12 serum protein biomarkers to assess disease activity in patients with RA. The…
Abstract Number: 1365 • 2017 ACR/ARHP Annual Meeting
Correlation of the Multi-Biomarker Disease Activity Score with Composite Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis
Tate Johnson¹, Kyle A. Register², Cynthia Schmidt³, James R. O'Dell⁴, Ted R. Mikuls⁵, Kaleb Michaud¹ and Bryant R. England⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ³McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The regular assessment of disease activity is necessary to implement a treat-to-target management approach in RA. The Multi-Biomarker Disease Activity (MBDA) Score is a…
Abstract Number: 2395 • 2017 ACR/ARHP Annual Meeting
Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements
Maria A. Lopez-Olivo¹, Ines Colmegna², Aliza Matusevich¹, Susan Ruyu Qi³, Natalia Zamora¹, Robin Sharma¹, Gregory Pratt⁴ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada, ³Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada, Montreal, QC, Canada, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: To compare the recommendations of clinical practice guidelines (CPGs) and consensus statements (CSs) regarding the management of rheumatoid arthritis (RA) in patients with cancer.…
Abstract Number: 2429 • 2017 ACR/ARHP Annual Meeting
Towards Precision Medicine in Rheumatoid Arthritis (RA): Trans-Ethnic Analysis and Prioritization of SNPs in the AFF3 Locus
Vincent A. Laufer¹, Maria I. Danila², Richard J. Reynolds³, Leah C. Kottyan⁴, Kenneth Kaufman⁵, John B. Harley⁶, Carl D Langefeld⁷, Donna Arnett⁸ and S. Louis Bridges Jr.⁹, ¹Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Center for Autoimmune Genomics and Etiology (CAGE), Division of Allergy and Immunology, Cincinnati Children's Hospital, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Wake Forest University, Winston Salem, NC, ⁸University of Kentucky College of Public Health, Lexington, KY, ⁹Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL
Background/Purpose: Genetic variants in AFF3 have been associated with RA, including in our GWAS and ImmunoChip analyses of African-Americans (610 RA; 1543 controls). Likewise, an…
Abstract Number: 536 • 2016 ACR/ARHP Annual Meeting
Precision Medicine in Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis on the Diagnostic Accuracy of Anti-CCP Tests for the Diagnosis of Rheumatoid Arthritis
Gaia Gallo¹, Barbara Mascialino¹, Donna Fountain², Kevin Cadwell² and Sigrid Sjolander¹, ¹Immuno Diagnostics, Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden, ²PHMR, Berkeley Works, Berkley Grove, London, London, United Kingdom
Background/Purpose: Biological markers are objective molecular indicators possessing diagnostic, prognostic and predictive utility. The detection of antibodies to cyclic citrullinated peptides (Anti-CCP) may occur long…
Abstract Number: 1490 • 2016 ACR/ARHP Annual Meeting
Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Claire Rempenault¹, Thomas Barnetche², Jacques Morel³, Cédric Lukas⁴, Cécile Gaujoux-Viala⁵, Bernard Combe⁶ and Charlotte Hua⁷, ¹Rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA) patients. Hydroxychloroquine (HCQ) has been shown to improve major outcomes like…
Abstract Number: 1627 • 2016 ACR/ARHP Annual Meeting
Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Steve Peterson¹, Maud Pacou², Drifa Belhadi², Suzy Van Sanden¹, Thomas Webb¹, Rita Ganguly³, Regina Kurrasch³, Ravi Rao³, Benjamin Hsu¹, Kaiyin Fei¹, Danuta Kielar¹ and Rafael Alfonso³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Amaris, Paris, France, ³GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human anti-interleukin-6 cytokine monoclonal antibody evaluated for the treatment of moderate to severe active rheumatoid arthritis (RA) and other diseases. Our…
Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Vidhu Anand¹, Sachit Anand², Sushil Garg³, Maria A. Lopez-Olivo⁴ and Jasvinder A. Singh⁵, ¹University of Minnesota, Minneapolis, MN, ²All India Institute of Medical Sciences, New Delhi, India, ³The University of Minnesota, Minneapolis, MN, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
Abstract Number: 1676 • 2015 ACR/ARHP Annual Meeting
Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update
Michelle E. Orme¹, Charles Hawes² and Stephen A. Mitchell³, ¹ICERA consulting UK, Swindon, United Kingdom, ²Pfizer UK, Surrey, United Kingdom, ³Abacus International UK, Bicester, United Kingdom
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (DMARDs) in combination with conventional DMARDs provide patients with severe rheumatoid arthritis (RA) and an inadequate response to conventional DMARDs…
Abstract Number: 1400 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolic Events in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies
Michelle Avina¹, Sally Choi², Sharan Rai³, Hyon K. Choi⁴ and Mary De Vera^3,5, ¹Faculty of Sciences, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Boston University School of Medicine, Boston, MA, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common vascular event after myocardial infarction…
Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial
Robin Christensen¹, Simon Tarp¹, Daniel Furst², Lars E. Kristensen³ and Henning Bliddal⁴, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²David Geffen School of Medicine, University of California, Los Angeles, CA, ³Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Simon Tarp¹, Daniel Furst², John R. Kirwan³, Maarten Boers⁴, Henning Bliddal⁵, Thasia Woodworth⁶, Else Marie Bartels⁷, Bente Danneskiold-Samsoe⁵, Lars Erik Kristensen⁸, Steffen Thirstrup⁹, Mette Rasmussen⁹, Marian Kaldas¹⁰ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, ⁶Leading Edge Clinical Research LLC, Florida, FL, ⁷Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Institute for Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark, ¹⁰David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…
Abstract Number: 1854 • 2012 ACR/ARHP Annual Meeting
The Safety of Anti-TNF Biologic Agents in Rheumatoid Arthritis – A Meta-Analysis of 35 RCTs
Tzuyu Lin¹, Tatyana Shamliyan¹, Hyon Choi², Young Hee Rho³ and Karen Kuntz¹, ¹Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: The objectives of this systematic review were to study and update the safety of anti-TNF agents. We examined whether etanercept (ETN), compared to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].